Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Cnbx Pharmaceutical Inc (CNBX)

Cnbx Pharmaceutical Inc (CNBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy PR Newswire - Tue Oct 18, 2022

/PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that...

CNBX : 0.0001 (unch)
CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel PR Newswire - Thu Oct 13, 2022

/PRNewswire/ - CNBX Pharmaceuticals Inc. (OTC-QB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that...

CNBX : 0.0001 (unch)
CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate PR Newswire - Thu Sep 29, 2022

/PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the...

CNBX : 0.0001 (unch)
CNBX Pharmaceuticals Announces New Patent Granted in Australia PR Newswire - Wed Sep 28, 2022

/PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that...

CNBX : 0.0001 (unch)

Barchart Exclusives

This Dividend Stock Has Been Steady Amid the Iran War: Is It Still a Buy? Barchart - 1 hour ago
Citigroup has a dividend yield of over 2.2% and has outperformed the markets over the last month. Is the stock still a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.